Betrixaban

• Target :

  Factor Xa

• Related Pathways :

  Metabolism

• Purity :

  0.9935

• Bioactivity :

  Betrixaban (PRT054021) is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa [1]. It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity [3]. Betrixaban, now developed by Portola Pharmaceuticals Inc., is prescribed as a venous thromboembolism (VTE) prophylactic for adult patients with moderate to severe restricted motility or with other risks for VTE [2]. VTE can be manifested as deep vein thrombosis or pulmonary embolism and it is a leading cause of preventable death in hospitalized patients [4].

• Smiles :

  COc1ccc(NC(=O)c2ccc(cc2)C(=N)N(C)C)c(c1)C(=O)Nc1ccc(Cl)cn1

• Molecular Formula :

  C23H22ClN5O3

• Molecular Weight :

  451.91

• Shipping Conditions :

  Cool pack

• Storage Temperature :

  -20°C

• CAS Number :

  330942-05-7